Loss in expression of ATRX protein was identified in 21.3% (19/89) cases and was more prevalent in WHO grade 4 IDH mutant astrocytomas (7/8; 87.5%) compared to IDH wildtype glioblastomas (12/81; 14.8%). This evidence concerns the gene ATRX and astrocytoma (excluding glioblastoma).